Targeting Endothelial Cell-Specific Molecule 1 Protein in Cancer: A Promising Therapeutic Approach

He Zhang1,2†, Yi-Wen Shen†, Li-Jun Zhang1, Jin-Jiao Chen1,2, Hui-Ting Bian1,2, Wen-Jie Gu1, Hong Zhang1, Hong-Zhuan Chen1,3, Wei-Dong Zhang1,4* and Xin Luan1*

1 Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China, 2 School of Pharmacy, Fudan University, Shanghai, China, 3 School of Medicine, Shanghai Jiao Tong University, Shanghai, China, 4 School of Pharmacy, Second Military Medical University, Shanghai, China

Despite the dramatic advances in cancer research in the past few years, effective therapeutic strategies are urgently needed. Endothelial cell-specific molecule 1 (ESM-1), a soluble dermatan sulfate proteoglycan, also known as endocan, serves as a diagnostic and prognostic indicator due to its aberrant expression under pathological conditions, including cancer, sepsis, kidney diseases, and cardiovascular disease. Significantly, ESM-1 can promote cancer progression and metastasis through the regulation of tumor cell proliferation, migration, invasion, and drug resistant. In addition, ESM-1 is involved in the tumor microenvironment, containing inflammation, angiogenesis, and lymphangiogenesis. This article reviews the molecular and biological characteristics of ESM-1 in cancer, the underlying mechanisms, the currently clinical and pre-clinical applications, and potential therapeutic strategies. Herein, we propose that ESM-1 is a new therapeutic target for cancer therapy.

Keywords: endothelial cell-specific molecule 1, endocan, cancer, cellular function, tumor microenvironment, targeted therapy

INTRODUCTION

With the development of molecular oncology and the advance of cancer diagnosis and treatment, there is a substantial reduction in both incidence and mortality (1). However, cancer is still one of the most challenging diseases in clinical practice, and effective therapeutic strategies are urgently needed. A comprehensive understanding of the molecular mechanism associated with cancer is essential for further development. In particular, some proteins play a pivotal role in cancer development and their expression levels are related to cancer diagnosis and prognosis (2). Endothelial cell-specific molecule 1 (ESM-1), also known as endocan, is a soluble dermatan sulfate (DS) proteoglycan. It is secreted by various cell lines, especially by human vascular endothelial cells, and can be detected in the human bloodstream (3).
Accidental discovery by French scientist Lassalle in 1996, ESM-1 was considered to be restricted in endothelial cells, therefore, it was named endothelial cell-specific molecule 1 (4). As ESM-1 is a kind of DS proteoglycan secreted specifically by endothelial cells, belonging to the PGs family, David Bechard renamed ESM-1 to endocan in 2001 (3).

DS is a glycosaminoglycan (GAG) which is produced through the epimerization of the glucuronic acid on chondroitin sulfate into iduronic acid by dermatan sulfate epimerase (DS-epi) 1 and 2. DS plays vital roles during the process of tumorogenesis, which is attributed to the increased flexibility of the polysaccharide chain in the presence of iduronic acid residues, facilitating specific interactions with proteins like growth factors, cytokines, and angiogenic factors (5, 6). As a kind of soluble DS proteoglycan, ESM-1 plays an important role in cancer initiation and progression. ESM-1 takes part in molecular interactions in a wide range of biological progresses, including cell proliferation, adhesion, migration, and invasion (7, 8). Moreover, ESM-1 has been implicated in vascular tissue development under normal or pathological conditions and it is often used as an indicator of angiogenesis in clinical practice. Studies have shown that ESM-1 is aberrantly expressed in a myriad of diseases, such as cancer, vascular disorder, and inflammation (9). Recently, ESM-1 has garnered immense attention owing to its distinctive role in tumorogenesis and tumor progression. In this review, we discussed the multifaceted role of ESM-1 in some important cellular processes relevant to cancer and the underlying mechanisms. The current therapeutic approaches targeting at ESM-1 are also comprehensively summarized.

THE STRUCTURE, EXPRESSION, AND REGULATION OF ESM-1

Located on chromosome 5 at the position q11.2, ESM-1 gene contains 3 exons and 2 introns with a total length of 2006 base pairs. Exon 1 and a part of exon 2 encode for a N-terminal cysteine-rich region of 110 amino acids residues. Besides, exon 2 encodes for the functional region rich in phenylalanine (F,113FPFFQY118) (10). Finally, exon 3 encodes for a short 33 amino-acid long C-terminal region that features the O-glycosylation site at serine 137 (3, 4, 11). The gene structure and protein sequence of ESM-1 is show in (Figure 1).

The initial coding protein of ESM-1 contains 184 amino acids. With the removal of the hydrophobic signal peptide sequence which is composed of 19 amino acid residues at the N-terminal, a mature protein containing 165 amino acids is formed. Taken together, ESM-1 is a 50 kDa cysteine-rich proteoglycan composed of 165 amino acids mature protein cores (20 kDa) and approximately 30 kDa corresponding to a unique dermatan sulfate chain linked to serine residues after being post-translationally modified (12, 13).

Originally, as ESM-1 is found at endothelial cells of lung tissue, scientists thought that ESM-1 is highly restricted to the lung vascular endothelial cells (4). Further studies revealed that ESM-1 also expressed in kidney, liver, lung, thyroid gland, lymph nodes, skin, and gastrointestinal tract (3, 13, 14). However, ESM-1 is not detected in vascular-rich organs such as heart, pancreas, and placenta (15).

The expression level of ESM-1 can be up-regulated by a multitude of proinflammatory cytokines and growth factors, such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-8 (IL-8), E-selectin, transforming growth factors-β1 (TGF-β1), lipopolysaccharide (LPS), nuclear factor-κB (NF-κB), phorbol myristate acetate (PMA), and retinoic acid (4, 13, 16–19). Vascular endothelial growth factor (VEGF) is a significant modulator which is capable of up-regulating the expression of ESM-1. Under the treatment of VEGF in vitro, expression of mRNA levels of ESM-1 is elevated in a time and dose-dependent manner (15). Interestingly, VEGF impacts on ESM-1 transcription through PKC-NF-κB signaling pathway, instead of Src or MEK/MAPK pathway (15, 20). In addition, ESM-1 is significant elevated in intermittent hypoxia (IH) compared to normoxia (21). IH plays a vital role in ESM-1 expression via HIF-1α/VEGF pathway. Under the condition of IH, HIF-1α is dramatically upregulated, and subsequently stimulates the expression of VEGF which is a positive regulator of ESM-1 (21).

FIGURE 1 | The gene structure and protein sequence of ESM-1. The gene structure of ESM-1. Exon 1 and part of exon 2 encode for an N-terminal cysteine-rich region. The exon 2 encodes a special region rich in F (113FPFFQY118), which is the functional region of ESM-1. The boundary between exon 1 and exon 2 encoding is the site of 82. Exon 3 encodes for a short 33 amino-acid long C-terminal region that includes the unique O-glycosylation site at serine 137.
In contrast, ESM-1 can be down-regulated by interleukin-4 (IL-4), interferon-γ (IFN-γ), phosphatidylinositol 3-kinase (PI3K), and homeodomain transcription factor (HHEX) (20, 22, 23). HHEX, a proline-rich homologous domain protein belonging to the homeobox family, can directly inhibit ESM-1 gene by binding to HRE which is the original HHEX responder in ESM-1 gene (24).

THE ROLE OF ESM-1 IN CANCER

Emerging evidence indicates that ESM-1 expression is elevated in a broad spectrum of cancers. It is also worth noting that the expression level of ESM-1 is related to tumor aggressiveness and tumor vascularization (8). In recent years, substantial investigations have focused on the relationship between ESM-1 and cancer. It has been found that ESM-1 is involved in many aspects of tumorigenesis, such as promoting cell cancerization, modulating cell proliferation and survival, as well as regulating migration and invasion (Figure 2). In addition, ESM-1 is closely related to drug resistance.

Promoting Cell Cancerization

Studies have shown that overexpression of ESM-1 in non-tumorigenic epithelial cells can induce tumor formation, while overexpression of ESM-1 in tumorigenic cells can significantly increase the growth rate of tumors (20, 25). Carcinogenesis of ESM-1 requires the existence of glycosylation chain and the integral protein structure, because specific protein mutations can lead to the loss of tumor promoting effect. The activity of ESM-1 in promoting tumor cell growth also depends on the protein core of ESM-1, especially the phenylalanine rich region centered on amino acid residues 115 and 116 (25). Yassine et al. in 2008 conducted a study on the role of ESM-1 in tumor progression in mice, showing that overexpression or systemic administration of endogenous non-glycosylated ESM-1 could delay the growth of HT-29 tumor cells. They believed that since human fully glycosylated ESM-1 can promote tumor growth, there is an interesting hypothesis that the balance between glycosylated ESM-1 and non-glycosylated ESM-1 can induce or delay tumor growth (10). Furthermore, ESM-1 can facilitate the transformation of dormant tumors into fast-growing angiogenic types and induce tumor formation (23, 24). Therefore, the cellular target of ESM-1 seems to be malignant epithelial cells rather than endothelium itself. It is speculated that ESM-1 protein plays a role in the paracrine positive feedback loop and facilitates tumor growth. Meanwhile, ESM-1 protein in turn plays a role in amplifying the effect of tumor growth factors and inhibiting the migration of effective immune cells into the tumor (4, 26).

Modulating Cell Proliferation and Survival

Previous studies have shown that ESM-1 can affect cell proliferation and cell survival. NF-κB is always secreted aberrantly in cancers, influencing the processes of oncogeneses such as cell proliferation and apoptosis, metastasis, and angiogenesis. On the basis of in-depth studies regarding the underlying mechanisms, researchers attributed the suppression of cell proliferation to the cell cycle arrest, which is a result of the regulation of NF-κB and PTEN by ESM-1 (26). Yun and his colleagues have found that knockdown of ESM-1 decreased the expression of NF-κB in colorectal cancer and hepatocellular...
cancer. In addition, PTEN, which plays a vital role in G1 cell cycle arrest, is activated after silencing ESM-1 and results in cell cycle protein cyclin D1 reduction and localization in the nucleus (27, 28).

Additionally, researchers found that the cell viability of the colorectal cancer cell lines COLO205 and SK-HEP1 was reduced up to 15% and 11% respectively after ESM-1 silencing (27, 28). Subsequent studies unraveled that ESM-1 increased tumor cell survival rate via the Akt-dependent NF-κB/1xB pathway. When the ESM-1 gene silenced, phospho-Akt and NF-κB subfamily members like NF-κB p65 were down-regulated and the phospho-1xBα was up-regulated, while the expression level of phospho-JNK or ERK1/2 was not altered. Interestingly, phospho-p38 MAPK was also decreased but phospho-Akt expression was more strongly suppressed than phospho-p38 MAPK expression in ESM-1 gene silencing cells compared to control. Taken together, JNK, ERK, and p38 pathways are not directly related to the suppression of survival (27, 28).

**Regulation of Migration and Invasion**

Cell migration and invasion are essential elements of cancer metastasis, which is responsible for nearly 90% of cancer-associated mortality (29). An interesting observation is that ESM-1 mRNA level is much higher in metastatic tumor samples than in non-metastatic tumor samples, indicating that ESM-1 expression is associated with metastasis (28). Moreover, ESM-1 is closely related to the vascular invasion. In gastric cancer, researchers found that tumors with ESM-1 overexpression show more easily invasion into vascular, causing more frequently distant metastasis (30).

During cancer invasion and metastasis, the surrounding basement membrane can be destroyed by expression of the transcript levels of matrix metalloproteinases (MMPs), making tumor cells drop from the primary focus and spread to new tissues. A recent study has shown that migration- and metastasis-associated proteins, such as MMP-9 were decreased by ESM-1 regulation and recombinant human (Rh) TIMP-1, a significant MMP-9 inhibitor, was increased by ESM-1 regulation. However, the ESM-1 mediated cell migration and invasion were enhanced. This may be attributed to the imbalance of MMP-9/TIMP-1, which is the mechanism of ESM-1 promoting metastasis of prostate cancer cells (31). ESM-1 expression significantly affects the migration of cells in colorectal, gastric, nasopharyngeal, head and neck cancer, and hepatocellular carcinomas (27, 28, 31, 32).

When silencing ESM-1 via siRNA, levels of NF-κB, phospho-Akt and glycogen synthase kinase 3 (GSK3α/β) are markedly decreased, whereas levels of E-cadherin are elevated. Akt and GSK3 have been proved to be involved in metastasis. GSK3 relates to the actin cytoskeleton, microtubules, and adhesion turnover in diverse stages of cell migration. These results indicate that ESM-1 expression may be related to cell migration and invasion (27, 31).

**Drug Resistance**

Traditional chemotherapy and emerging molecularly targeted therapies have significantly improved the efficacy of cancer therapeutics. However, drug resistance remains a major obstacle for cancer treatment, resulting to tumor cells insensitive to chemotherapeutic drugs and/or other anti-cancer drugs. Usually, the development of drug resistance involves a series of gene and protein interactions (33, 34). Previous studies have revealed that ESM-1 is one of drug resistance-related genes (35). In patients with prolactinoma, ESM-1-microvessel density in bromocriptine (which belongs to dopamine agonist to treat prolactinoma) resistant patients was dramatically higher than that of sensitive groups. However, blocking ESM-1 with siRNAs markedly increased the sensitivity of rat prolactinoma cell lines GH3 and MMQ to dopamine agonist treatment (35). Similar observation has been made in HUVEC cells. Silencing of ESM-1 significantly increased the sensitivity of HUVECs to bevacizumab to treatment (35).

**THE ROLE OF ESM-1 IN TUMOR MICROENVIRONMENT**

Tumors are dynamic entities which grow in a highly complex milieu called tumor microenvironment (TME). TME encompasses not only tumor cells, but also multiple other components like immune cells, endothelial cells, adipocytes, fibroblasts, extracellular matrix (ECM), as well as blood and lymph vessels (36). The intricate microenvironment affects tumor growth, invasion, and metastasis. Mounting evidence indicates that targeting TME may provide a reliable alternative to conventional tumor-targeted therapy (37).

**ESM-1 and Inflammation**

Inflammation is strongly associated with cancer. There is a growing body of evidence indicating that inflammation contributes to the development and progression of malignancies (38, 39), and it is regarded as one of hallmarks of cancer (40). It has been demonstrated that ESM-1 can influence leukocyte adhesion and extravasation, which are essential for inflammatory processes. Researches show that ESM-1 can reduce leukocyte adhesion by directly binding to leukocyte function-associated antigen-1 (LFA-1) in vitro (41). LFA-1, an integrin molecule, interacts with its most important ligand intercellular adhesion molecule-1 (ICAM-1), promoting leukocytes adhesion to endothelial cells (42, 43). ESM-1 has been found to directly bind to LFA-1 on the cell surface of leukocytes, and antagonize interaction with endothelial-cell expressed ICAM-1, reducing leukocyte adhesion in vivo (41). However, leukocyte-to-endothelial cell adhesion was not reduced by ESM-1 in a biomimetic microfluidic assay by Zheng et al. (44). This data suggests that LFA-1 is not the only adhesion molecule on leukocytes that binds to ICAM-1 (44). To further investigate the impact of ESM-1 on leukocyte in vivo, researchers performed peritonitis assays on ESM-1 knockout mice and wild type mice. ESM-1 knockout mice showed a significant decrease in leukocyte extravasation compared with wild mice, indicating ESM-1 plays an important role in leukocyte extravasation (45). Moreover, researchers used the intravital microscopy to direct visualization and analysis of leukocyte behavior during the rolling, adhesion, and transmigration steps. They found that the impaired leukocyte extravasation in ESM-1 knockout mice was attributed to reduced transmigration. Immunostainings for leukocyte-endothelial cells adherens and tight junctions show that there are no significant
structural differences between ESM-1 knockout mice and wild type mice (45). Therefore, targeting ESM-1 could be a promising strategy to treat inflammation and cancer.

**Regulation of Angiogenesis**

Tumor vascularization is a hallmark of cancer and has been shown as an important step in cancer progression and metastasis (46). The VEGF pathway is one of the key mediators of angiogenesis in cancer. As mentioned above, VEGF-A is a specific inducer of ESM-1 transcription which is supported by the fact that ESM-1 expression is up-regulated in VEGF-A treated endothelial cells (20). Notably, emerging studies have identified that ESM-1 is also implicated in angiogenesis (Figure 2). ESM-1 is overexpressed during in vitro angiogenesis. However, ESM-1 seems not to modify angiogenesis directly (17), as HUVEC tube formation induced by VEGF and FGF-2 did not change after ESM-1 knockdown (47). Mechanistic investigations on the role of ESM-1 in angiogenesis revealed that there is a positive feedback loop between VEGF-A and ESM-1. ESM-1 expression was stimulated by VEGF-A through the phosphorylation and activation of VEGFR-2 (48). In turn, ESM-1 binds to fibronectin directly and thereby displaces fibronectin-bound VEGF-A$_{165}$, resulting in increased bioavailability of VEGF-A$_{165}$ and subsequently enhanced VEGF-A mediated signaling (45). Consistent with this, researchers found that more VEGF-A$_{165}$ is sequestered to fibronectin and decreases VEGF bioavailability and signaling after ESM-1 knockdown (45). Moreover, it has been reported that ESM-1 is enriched in specialized tip cells and is associated with filopodia (49–51). The tip cells are one of the motile endothelial cells, which mediate the sprouting of developing vessels during the process of angiogenesis (52). Filopodia are typically present in tip cells and are needed for their guidance and motility during angiogenesis. In ESM-1 knockout mice retina models, retinal vascular outgrowth and filopodia emission are impaired. In further studies, F. Rocha et al. found that filopodia number is significantly decreased after ESM-1 knockdown and the impaired vascular progression might be due to the reduction of motility of endothelial sprouts (45).

In addition, ESM-1 can bind to HGF/SF, FGF-2 and other proangiogenic molecules, exerting the effect of angiogenesis promotion. The DS chain of ESM-1 can bind to HGF/SF and FGF-2 and promote the proliferation of vascular endothelial cells, resulting in neovascularization. ESM-1 and HGF/SF, FGF-2 can promote the expression of each other in the form of positive feedback regulation, which makes vascular endothelial cell proliferation more obvious and easier to form tubular structure (4).

**Regulation of Lymph Angiogenesis**

Tumor lymphatic vessels execute complex functions during cancer progression. Metastatic tumor cells readily invade permeable peritumoral lymphatic vessels and metastasis (53). Moreover, tumors can induce lymph angiogenesis within their draining lymph nodes even before metastasis and induce lymph angiogenesis in lymph nodes, promoting the further metastasis to distant lymph nodes and organs (12).

Previous studies have shown that the growth and activation of lymphatic vessels can be mediated by VEGF-C and/or VEGF-A. Of note, ESM-1 can be potently induced by both VEGF-C and VEGF-A during lymph angiogenesis (Figure 2). A follow-up study revealed that incubation of lymphatic endothelial cells (LECs) with ESM-1 enhanced the stimulating effects of both VEGF-A and VEGF-C on LEC proliferation and migration, whereas incubation with ESM-1 alone did not have the same effect. However, gene silencing of ESM-1 significantly inhibited the induction of LEC proliferation and migration by VEGF-A and/or VEGF-C. Taken together, ESM-1 induced by VEGF-A and/or VEGF-C represents an autocrine, positive feedback loop which further promote the stimulatory functions of both growth factors on lymphatic endothelial cells. Moreover, ESM-1 induction by VEGF-A was mainly dependent on the activation of VEGFR-2, as inhibition of VEGFR-2 completely inhibits the VEGF-A mediated induction of ESM-1 in LECs. And VEGF-C mediated induction depended on the activity of both VEGFR-2 and VEGFR-3 (12). In brief, ESM-1 can enhance the function of other lymphangiogenic factors (such as VEGF-A, VEGF-C) to indirectly promote lymph angiogenesis and tumor metastasis. It can be a novel mediator of lymph angiogenesis and regarded as a potential target for the inhibition of VEGF-A– or VEGF-C–induced pathologic lymphatic vessel activation.

**CLINICAL RELEVANCE OF ESM-1 IN CANCERS**

ESM-1 protein is aberrantly expressed in many cancers, including hematologic and solid tumors (Table 1). The over- or under-expression of ESM-1 compared to normal tissues is related to worse clinicopathologic features and clinical outcomes, indicating the ESM-1 as a biomarker for diagnosis and prognosis.

As ESM-1 is a secreted protein, it is a potential marker for cancer. In gastric cancer, higher serum ESM-1 level is related to poor prognosis (63). In non-small cell lung cancer, ESM-1 level is higher in malignant pleural effusion (MPE) compared with benign pleural effusion (BPE), and is associated with poor prognosis and distant metastasis (67). ESM-1 is also an indicator for the aggressive behavior of cancer. Although barely expressed in endothelial cells of normal pituitary, ESM-1 is highly expressed in endothelial and/or endocrine cells in patients with pituitary adenomas (70). In addition, the higher ESM-1 level indicates bigger tumor size, raised mitotic count and elevated p53 expression (70). In gastric cancer, ESM-1 is strikingly overexpressed in tumor tissue, resulting in tumor proliferation, distant lymph nodes metastasis, as well as vascular invasion (30, 62). In addition, ESM-1 is related to Borrmann type IV which is an independent prognosis factor for survival in gastric cancer (30, 75).

Interestingly, ESM-1 is only enhanced in triple negative breast cancer (TNBC), the most aggressive and easily metastatic breast cancer subtype, and its expression is positively correlated with the malignancy of cancer. MDA-MB-231BR is a brain metastatic variant of human TNBC cell line MDA-MB-231 and is more malignant than MDA-MB-231 cells. ESM-1 is strikingly overexpressed in MDA-MB-231BR, which might be due to DNA demethylation in an upstream region of ESM-1 gene (55).

Although there are a series of clinicopathologic parameters aiming different cancers, novel and effective biomarkers are still
urgently needed to improve the clinical prediction of cancer progression and recurrence. In addition, thoroughly understanding the relationship between ESM-1 expression and the subsistent clinicopathological characters of cancers is helpful for combining diagnosis. In pituitary adenomas, ESM-1 is positively correlated to Knosp tumor invasion grades, which is useful to estimate the degree of invasion by ESM-1 expression (71). In multiple myeloma, ESM-1 is elevated in plasma and is associated with disease stage, hypercalcemia, renal failure, anemia, and bone lesions. The additional secretion of ESM-1 may attribute to the secretion of VEGF by malignant plasma cells and the interaction with bone marrow microenvironment (66). In prostate cancer, ESM-1 expression is significantly elevated in patients with high Gleason grades and Gleason scores, the main method used to stage prostate cancer, suggesting ESM-1 is a useful biomarker for cancer diagnosis (74).

In addition, ESM-1 is a potential parameter to monitor the tumor response to anti-angiogenic therapeutics. An interesting observation in clear cell renal cell carcinoma is that sunitinib can prevent VEGF-induced ESM-1 secretion by endothelial cells, but not regulate the TNF-α-induced ESM-1 secretion (56), suggesting that ESM-1 could be a potential biomarker to monitor the patient response to anti-VEGF therapies (56).

Angiogenesis is crucial for cancer progression and is an indicator for poor prognosis. It is worthy to note that ESM-1 is also a biomarker of neovascularization, the hallmark of tumor development, invasion, and metastasis (40). Angiogenesis is always evaluated by tumor microvascular density (MVD) that is counting CD-31 or CD-34 antibodies positive vessels (60). Nevertheless, the major defect is that these antibodies will mark endothelial cells of both normal and tumor tissues (76). Therefore, it is necessary to find a highly specific marker to label the endothelium of tumor tissue but not with the endothelium of most normal tissue. As mentioned above, ESM-1 is over-expressed in tumor tissues but under-expressed in normal tissues. Mounting evidence indicates that the MVD denoted by ESM-1 (ESM-1-MVD) has prognostic value in malignancy that higher ESM-1-MVD is correlated with a shorter survival time. In addition, ESM-1-MVD was strongly associated with tumor histology, grading, tumor size, and clinical staging, and has been proven to be one of the most accurate prognostic indicators of postoperative recurrence in ovarian cancer (60), gastric cancer (76, 77), and hepatocellular carcinoma (64). Taken together, ESM-1-MVD is a useful marker for prognosis, which can identify those who might benefit from a different follow-up approach and subsequent adjuvant therapy.

### THERAPEUTIC STRATEGIES TARGETING ESM-1 IN CANCER

Given the intimate relationship between ESM-1 and tumor biology, ESM-1 promises to be an CD11a/CD18 active target in cancer therapy. Tremendous efforts have been made or underway to explore the potential value of modulating ESM-1.

| Cancers                                      | Research sample | Expression level | Clinical characterization                                                                 | Reference |
|----------------------------------------------|-----------------|------------------|------------------------------------------------------------------------------------------|-----------|
| Bladder Cancer                               | Tissue          | High             | Shorter recurrence-free survival time in noninvasive bladder cancers                      | (48, 54)  |
| Breast cancer (TNBC)                         | Plasma          | High             | Poor outcome                                                                             | (55)      |
| Clear cell renal cell carcinoma              | Serum           | High             | Poor Survival                                                                            | (56)      |
| Colorectal cancer                            | Serum           | High             | Poor prognosis, high histological differentiation, high depth of tumor invasion high TNM stage and high lymph node metastasis | (57, 58)  |
| Ovarian cancer                               | Tissue          | Lower            | Poor differentiate                                                                      | (59)      |
| Gastric cancer                               | Tissue          | High             | More malignancy                                                                          | (61)      |
| Tissue                                       | High             | Poor survival    | Distant and lymph nodes metastasis                                                      | (30, 62)  |
| Hepatocellular Carcinoma                     | Serum           | High             | Poor prognosis                                                                          | (63)      |
| Meningiomas and Gliomas                      | Tissue          | High             | High tumor stage                                                                         | (28)      |
| Multiple myeloma                             | Serum           | High             | Poor degree of malignancy                                                                | (65)      |
| Non-small cell lung cancer                   | Tissue          | High             | Poor prognosis and distant metastasis                                                    | (17)      |
| Pleural effusion                             | Tissue          | High             | Poor prognosis, poor survival and distant metastasis                                     | (67)      |
| Oral cancer                                  | Plasma          | High             | Associated with tumor (T) status, higher at T1-T3 status                                 | (68)      |
| Pancreatic neuroendocrine tumors              | Tissue          | High             | Poor clinical outcomes and greater malignancy                                           | (69)      |
| Pituitary adenoma                            | Tissue          | High             | Associated with Knosp tumor invasion grades, higher recurrence, more aggressive and invasion | (70–72)  |
| Prostate cancer                              | Serum           | High             | Easily recurrence                                                                        | (73)      |
| Tissue                                       | High             | Higher Gleason grades and scores                                                       | (74)      |

TNBC, Triple-negative breast cancer; TNM, Tumor node metastasis.
for cancer treatment in experimental and clinical settings. However, there are no small molecular drugs targeting ESM-1 in clinic currently. This may be attributed to the indeterminacy of ESM-1 protein crystal structure. Hence, there are still many difficulties in developing drugs targeting ESM-1.

**Exon 2 Deletion of ESM-1 Could be a Future Cancer Therapy Target**

The biologic functions of proteoglycans often depend on the interactions of their glycosaminoglycan chains with protein ligands, such as cytokines and growth factors (78, 79). As ESM-1 is a kind of proteoglycans which is involved in tumor development, the glycosylation chain is essential for its biological activity. Researchers demonstrate that the tumorigenic property of ESM-1 is highly dependent on its glycan chain. In addition, the protein core and a Phenylalanine-rich (F-rich) region situated between residues F113 and F116 are also critical (80).

Depontieu et al. identified exon 2 sequence is closely connected with protein multimerization, the glycation status, and the cancerogenic activity of ESM-1. Deletion of exon 2 related amino acid sequence (called ESM-1A2) impaired the synthesis of glycan chain, and ESM-1A2 loss the function of cancerization. Moreover, various cell lines of human and murine origin were implanted in the skin of severe combined immunodeficient mice, and ESM-1A2 did not promote tumor formation. These suggesting that exon 2-derived sequence may represent a future therapeutic target against cancer (80).

**Silencing ESM-1 by RNAi and Antibody**

**siRNA and shRNA**

The high expression and sustained activation of ESM-1 is prevailing in tumor cells and ESM-1 is recognized as a highly dependent gene for survival. RNA interference technology, a highly functional tool for researchers to prevent pathogenic gene expression, was mainly used to study the function of a gene or disease (81).

A broad array of genetic knockdown experiments validated the potential of ESM-1 as a powerful target for clinical evaluation in the treatment of cancer. Blocking ESM-1 with small interfering RNAs (siRNAs) successfully inhibited tumor cell proliferation, migration, invasion, and angiogenesis in diverse cancers (Table 2). Moreover, ESM-1 knockdown with short hairpin RNAs (shRNAs) dramatically inhibit the NGFR induced tumor growth, invasion, and metastasis in oral squamous cell carcinoma (84).

Despite the initially encouraging ESM-1 knockdown outcomes in vivo, most reports utilized the gene silencing techniques in cultured cells, and less is known about how malignant cells response to blockade agents in established tumors. The research and development of RNAi targeting ESM-1 have great potential in the future.

**miRNA**

MicroRNAs (miRNAs) are endogenous, small non-coding RNAs which contain about 20 to 25 nucleotides, and play regulatory roles in target gene expression by complexing with RNA-induced silencing complexes (RISCs) and interacting with the 3’ untranslated regions (3’UTRs) of target mRNAs (85–87). Since ESM-1 are upregulated in many cancers, interference with ESM-1 by miRNA may be a potential therapeutic strategy.

As reported, miR-9-3p, derived from bone marrow-derived mesenchymal stem cells (BMSCs) secreted exosomes, can target gene ESM-1 to inhibit viability, migration, and invasion while promoting apoptosis in bladder cancer cells. Additionally, ESM-1 is down-regulation after exosomal miR-9-3p treatment, and the cancer progression and metastasis are both prevented in xenograft model of bladder cancer in mice (88).

Despite miRNA therapeutic strategy is a promising treatment approach to cancer, there are several questions remain to be addressed. MiRNA is a multiple targeted regulator which often regulates multiple miRNAs, as mRNA recognition only requires binding to the 5’- end of the seed region of miRNA rather than the entire nucleotide sequence (89, 90). Hence, it is essential to develop a method to deliver miRNA to tumor cells at the target site, which can improve cell specificity. Besides, it is necessary to develop effective delivery systems to protect miRNA escaping degraded by serum nucleases, removed by immune system, and to increase the target cell uptake.

**Antibody**

With the approval of bevacizumab (Avastin) and cetuximab (Erbitux), antibody-based therapeutics appear to be vital for cancer treatment in experimental and clinical settings. However, there are no small molecular drugs targeting ESM-1 in clinic currently. This may be attributed to the indeterminacy of ESM-1 protein crystal structure. Hence, there are still many difficulties in developing drugs targeting ESM-1.

**Exon 2 Deletion of ESM-1 Could be a Future Cancer Therapy Target**

The biologic functions of proteoglycans often depend on the interactions of their glycosaminoglycan chains with protein ligands, such as cytokines and growth factors (78, 79). As ESM-1 is a kind of proteoglycans which is involved in tumor development, the glycosylation chain is essential for its biological activity. Researchers demonstrate that the tumorigenic property of ESM-1 is highly dependent on its glycan chain. In addition, the protein core and a Phenylalanine-rich (F-rich) region situated between residues F113 and F116 are also critical (80).

Depontieu et al. identified exon 2 sequence is closely connected with protein multimerization, the glycation status, and the cancerogenic activity of ESM-1. Deletion of exon 2 related amino acid sequence (called ESM-1A2) impaired the synthesis of glycan chain, and ESM-1A2 loss the function of cancerization. Moreover, various cell lines of human and murine origin were implanted in the skin of severe combined immunodeficient mice, and ESM-1A2 did not promote tumor formation. These suggesting that exon 2-derived sequence may represent a future therapeutic target against cancer (80).

**Silencing ESM-1 by RNAi and Antibody**

**siRNA and shRNA**

The high expression and sustained activation of ESM-1 is prevailing in tumor cells and ESM-1 is recognized as a highly dependent gene for survival. RNA interference technology, a highly functional tool for researchers to prevent pathogenic gene expression, was mainly used to study the function of a gene or disease (81).

A broad array of genetic knockdown experiments validated the potential of ESM-1 as a powerful target for clinical evaluation in the treatment of cancer. Blocking ESM-1 with small interfering RNAs (siRNAs) successfully inhibited tumor cell proliferation, migration, invasion, and angiogenesis in diverse cancers (Table 2).

### TABLE 2 | List of therapeutic strategies targeting ESM-1.

| Intervention | Cancer type | Results | Reference |
|-------------|-------------|---------|-----------|
| siRNA       | Colorectal cancer | Inhibit migration, invasion and decrease cell survival | (26, 54) |
|             | Hepatocellular carcinoma | Decrease cell survival, migration, and invasion and modulated cell cycle progression | (28) |
|             | Head and neck cancer | Inhibit proliferation, migration | (81) |
|             | Invasive Bladder Cancer | Inhibit VEGF-A–induced tube formation, migration, and VEGFR-2 phosphorylation | (48) |
|             | Gastric cancer | Inhibit proliferation | (62) |
|             | Prostate cancer | Inhibit migration | (73, 82) |
|             | Triple-negative breast cancer | Inhibit proliferation, colony, migration, invasion | (83) |
| shRNA       | Oral squamous cell carcinoma | Inhibit NGFR-induced the tumor growth, invasion, and metastasis | (84) |
| Antibody (PABsc-20343) | Gastric cancer | Inhibit tumor cells and vascular endothelial cells proliferation | (29) |
| miR-9-3p    | Bladder cancer | Inhibit viability, migration, and invasion, and promote apoptosis | (85) |

*VEGF-A, Vascular endothelial growth factor A; VEGFR-2, Vascular endothelial growth factor receptor 2; NGFR, Nerve growth factor receptor.*
components of therapies for multiple cancers (91). Although ESM-1 is a kind of secreted protein which is suitable for monoclonal antibody blockade, the research on anti-ESM-1 antibody is limited. In gastric cancer, ESM-1 overexpressed endothelial cells HMEC-1 and adenocarcinoma cells MKN28 are treated with a goat polyclonal antibody (PABsc-20343) to antagonize ESM-1. As a result, there is a marked reduction of cell numbers, suggesting that down-regulation of ESM-1 can inhibit tumor cells and vascular endothelial cells proliferation (30).

CONCLUSIONS

ESM-1 is an endothelial dysfunction marker and participates in diverse endothelium-dependent pathological disorders, including cancer, sepsis, kidney diseases and cardiovascular disease (25, 92, 93). Herein, we have attempted to shed light on the unique role of ESM-1 in cancers. It is worth noting that ESM-1 is not only intrinsically promoting tumor growth, but also regulating tumor microenvironment. In addition, ESM-1 is a biomarker for diagnosis and prognosis of cancers.

Given the significant role of ESM-1 in cancers, it may be a potential target in cancer treatment, and the inhibitors targeting ESM-1 are urgently needed. Hindered by lack of precise ESM-1 crystal structure, the design-based small-molecule inhibitor discovery and identification, has lagged. The utilization of advanced molecular biology techniques, such as RNAi, to target ESM-1 have shown encouraging results. However, these methods are only used in vitro or in animal models, due to the failure to reach the target organs or tissues specifically. Nanocarriers provide us with a novel delivery system to protect RNAs and antibodies from degradation in blood vessels, deliver them to target organs, and promote intracellular accumulation. Taken together, further studies are required to completely clarify the regulations of ESM-1 and the underlying mechanisms under different physiological conditions.

AUTHOR CONTRIBUTIONS

W-DZ, XL contributed to conceptualization, review and editing, funding acquisition, and supervision. HeZ and Y-WS carried out the original draft, made figures and wrote the paper. L-JZ, J-JC, H-TB, W-JG, HoZ, and H-ZC revised the paper. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the National Natural Science Foundation of China (No.81903654), Program for Professor of Special Appointment (Young Eastern Scholar) at Shanghai Institutions of Higher Learning (QD2018035), Shanghai Chenguang Program (No.18CG46), Shanghai Sailing Program (19YF1494900), Shanghai Engineering Research Centre for the Preparation of Bioactive Natural Products (16DZZ2280200), the National Key Research and Development Program of China (2017YFC1700200), and the National Major Project of China (2019ZX09201004-003-010).

REFERENCES

1. Rong BX, Cai XG, Liu H, Yang SY. Stathmin-Dependent Molecular Targeting Therapy for Malignant Tumor: The Latest 5 Years’discoveries and Developments. J Transl Med (2016) 14:297. doi: 10.1186/s12967-016-1000-z
2. Rong B, Yang S. Molecular Mechanism and Targeted Therapy of Hsp90 Involving in Lung Cancer: New Discoveries and Developments. Int J Oncol (2018) 52(2):321–36. doi: 10.3892/ijo.2017.4214
3. Béchard D, Gentina T, Delehedde M, Scherpereel A, Lyon M, Aumercier M, et al. Endocan is a Novel Chondroitin Sulfate/Dermatan Sulfate Proteoglycan That Promotes Hepatocyte Growth Factor/Scatter Factor Mitogenic Activity. J Biol Chem (2001) 276(51):48341–9. doi: 10.1074/jbc.M108395200
4. Lassalle P, Molet S, Janin A, Van der Heyden J, Tavernier J, Fiers W, et al. ESM-1 is a Novel Human Endothelial Cell-Specific Molecule Expressed in Lung and Regulated by Cytokines. J Biol Chem (1996) 271(34):20458–64. doi: 10.1074/jbc.271.34.20458
5. Yamada S, Sugahara K. Potential Therapeutic Application of Chondroitin Sulfate/Dermapan Sulfate. Curr Drug Discov Technol (2008) 5(4):289–301. doi: 10.2174/157016308786733564
6. Listik E, Xavier EG, Silva PM, Toma L. Dermatan Sulfate Epimerase I Expression and Mislocalization may Interfere With Dermatan Sulfate Synthesis and Breast Cancer Cell Growth. Carbohydr Res (2020) 488:107906. doi: 10.1016/j.carres.2020.107906
7. Kali A, Shetty KS. Endocan: A Novel Circulating Proteoglycan. Indian J Pharmacol (2014) 46(6):579–83. doi: 10.4103/0253-7613.144891
8. Abu EA, Nawaz MI, De Hertogh G, Al-Kharashi AS, Van den Eynde K, Mohammad G, et al. The Angiogenic Biomarker Endocan is Upregulated in Proliferative Diabetic Retinopathy and Correlates With Vascular Endothelial Growth Factor. Curr Eye Res (2015) 40(3):321–31. doi: 10.3109/02713683.2014.921312
9. Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, et al. Endocan or Endothelial Cell Specific Molecule-1 (ESM-1): A Potential Novel Endothelial Cell Marker and a New Target for Cancer Therapy. Biochim Biophys Acta (2006) 1765(15)25–37. doi: 10.1016/j.bbamcr.2005.08.004
10. Scherpereel A, Gentina T, Grigoriu B, Senechal S, Janin A, Tsicopoulos A, et al. Overexpression of Endocan Induces Tumor Formation. Cancer Res (2003) 63(18):6084–9.
11. Sarrazin S, Lyon M, Deakin JA, Guerrini M, Lassalle P, Delehedde M, et al. Characterization and Binding Activity of the Chondroitin/Dermatan Sulfate Chain From Endocan, a Soluble Endothelial Proteoglycan. Glycoconj. J (2010) 20(11):1380–8. doi: 10.1007/glycob/cwq100
12. Shin JW, Huggenberger R, Detmar M. Transcriptional Profiling of VEGF-A and VEGF-C Target Genes in Lymphatic Endothelium Reveals Endothelial-Specific Molecule-1 as a Novel Mediator of Lymphangiogenesis. Blood (2008) 112(6):2318–26. doi: 10.1182/blood-2008-05-156331
13. Bechard D, Meignin V, Scherpereel A, Oudin S, Kervoaze G, Bertheau P, et al. Characterization of the Secreted Form of Endothelial-Cell-Specific Molecule 1 by Specific Monoclonal Antibodies. J Vasc Res (2000) 37(5):417–25. doi: 10.1159/000025758
14. Zhang SM, Zuo L, Zhou Q, Gui SY, Shi R, Wu Q, et al. Expression and Distribution of Endocan in Human Tissues. Biochim Biophys Acta Histochem (2012) 87(3):172–8. doi: 10.3109/10520295.2011.577754
15. Abid MR, Yi X, Yano K, Shih S, Aird WC. Vascular Endocan is Preferentially Expressed in Tumor Endothelium. Microvasc Res (2006) 72(3):136–45. doi: 10.1016/j.mvr.2006.05.010
16. Scherpereel A, Depontieu F, Grigoriu B, Cavestri B, Tsicopoulos A, Gentina T, et al. Endocan, a New Endothelial Marker in Human Sepsis. Crit Care Med (2006) 34(2):532–7. doi: 10.1097/01.ccm.0000198525.82124.74
17. Grigoriu BD, Depontieu F, Scherpereel A, Gourcerol D, Devos P, Ouatas T, et al. Endocan Expression and Relationship With Survival in Human Non-
Kang YH, Ji NY, Lee CI, Lee HG, Kim JW, Yeom YI, et al. ESM-1 Silencing
Rasmi RR, Sakthivel KM, Guruvayoorappan C. NF-kappaB Inhibitors in
Kang YH, Ji NY, Han SR, Lee CI, Kim JW, Yeom YI, et al. ESM-1 Regulates
De Freitas CN, Gaudet A, Portier L, Tsicopoulos A, Mathieu D, Lassalle P.
30. Liu N, Zhang L, Du H, Hu Y, Zhang G, Wang X, et al. Overexpression of
Cong R, Jiang X, Wilson CM, Hunter MP, Vasavada H, Bogue CW. Hhex is a
Maurage CA, Adam E, Mineo JF, Sarrazin S, Debunne M, Siminski RM,
Sun H, Zhang H, Li K, Wu H, Zhan X, Fang F, et al. ESM-1 Promotes
Rennel E, Mellberg S, Dimberg A, Petersson L, Botling J, Ameur A, et al.
Chen CM, Lin CL, Chiou HL, Hsieh SC, Lin CL, Cheng CW, et al. Loss of
Frontiers in Oncology | www.frontiersin.org May 2021 | Volume 11 | Article 6871209
Zhang et al. Targeting ESM-1 in Cancer
Progression in Hepatocellular Carcinoma.
doi: 10.1007/s00726-010-0729-6
Oncogenes
doi: 10.1186/s13054-018-2222-7
van Oeffelen With Susceptibility to Diabetic Nephropathy. PloS One (2017) 12
Roche SF, Schiller M, Jing D, Li H, Butz S, Westveder D, et al. Esml Modulates
The Next Generation.
doi: 10.1016/j.circressha.115.304718
Donovan P, Patel J, Dight J, Wong HY, Sim SL, Murigneux V, et al. Endovascular Progenitors Infiltrate Melanomas and Differentiate Towards a Variety of Vascular Beds Promoting Tumor Metastasis. Nat Commun (2019) 10(1):18. doi: 10.1038/s41467-018-0796-w
Atikemhead M, Wang S, Nakatsu MN, Mesata J, Heard C, Hughes CCW. Identification of Endothelial Cell Genes Expressed in an In Vitro Model of Angiogenesis: Induction of ESM-1, Ilg-h3, and Nrcam. Microvasc Res (2002) 63(2):159–71. doi: 10.1006/mvre.2001.2380
Roudnicky F, Poyet C, Wild P, Krampitz S, Negrini F, Huggenberger R, et al. Endocan is Upregulated on Tumor Vessels in Invasive Bladder Cancer Where it Mediates VEGF-A-induced Angiogenesis. Cancer Res (2013) 73(3):1097–1106. doi: 10.1158/0005-8215.CAN-12-1855
Recchia FM, Xu L, Penn JS, Boone B, Drexheimer PJ. Identification of Genes and Pathways Involved in Retinal Neovascularization by Microarray Analysis of Two Animal Models of Retinal Angiogenesis. Invest Ophthalmol Vis Sci (2010) 51(2):1098–105. doi: 10.1167/iovs.09-4006
Strasser GA, Kaminker JS, Tessier-Lavigne M. Microarray Analysis of Retinal Endothelial Tip Cells Identifies Cxcr4 as a Mediator of Tip Cell Morphology and Branching. Blood (2010) 115(24):5102–10. doi: 10.1182/blood-2009-07-230284
Del TR, Prahat C, Mathivet T, Siegfried G, Kaminker JS, Larrivee B, et al. Identification and Functional Analysis of Endothelial Tip Cell-Enriched Genes. Blood (2010) 116(19):4025–33. doi: 10.1182/blood-2010-02-270819
Haupt F, Krishnasamy K, Napp LC, Augustynik M, Limbourg A, Gamrekelashvili J, et al. Retinal Myeloid Cells Regulate Tip Cell Selection and Vascular Branching Morphogenesis Via Notch Ligand Delta-like 1. Sci Rep (2019) 9(1):9798. doi: 10.1038/s41598-019-46308-3
Petrova TV, Koh GY. Biological Functions of Lymphatic Vessels. Science (2020) 369(65):eaax4063. doi: 10.1126/science.aa0463
Lalouglu A, Aksoy H, Aksoy F, Ozkaya F, Akcay F. The Determination of Urinary Endocan Concentrations in Patients With Bladder Cancer. Ann Clin Biochem (2016) 53(6):647–53. doi: 10.1177/000456316269169
Sagara A, Igarashi K, Otsuka M, Kodama A, Yamashita M, Sugiura R, et al. Endocan as a Prognostic Biomarker of Triple-Negative Breast Cancer. Breast Cancer Res Treat (2017) 161(2):269–78. doi: 10.1007/10549-016-4057-8
Leroy X, Aubert S, Zini L, Frassetto H, Kervoisez G, Villers A, et al. Vascular Endocan (ESM-1) is Markedly Overexpressed in Clear Cell Renal Cell Carcinoma. Histopathology (2010) 56(2):180–7. doi: 10.1111/j.1365-2559.2009.03458.x
57. Ji NY, Kim Y, Jang YJ, Kang YH, Lee CI, Kim JW, et al. Identification of Endothelial Cell-Specific Molecule-1 as a Potential Serum Marker for Colorectal Cancer. Cancer Sci (2010) 101(10):2248–53. doi: 10.1111/j.1349-7006.2010.01665.x

58. Jiang H, Fu XG, Chen YT. Serum Level of Endothelial Cell-Specific Molecule-1 and Prognosis of Colorectal Cancer. Genet Mol Res (2015) 14(2):5519–26. doi: 10.4238/2015.May.25.3

59. Zuo L, Zhang S, Hu R, Zhu H, Zhou Q, Gui S, et al. Correlation Between Expression and Differentiation of Endocan in Colorectal Cancer. World J Gastroenterol (2008) 14(28):4562. doi: 10.3748/wjg.v14.i28

60. El Behery MM, Seksaka MA, Ibrahim MA, Saleh HS, El Alfy Y. Clinicopathological Correlation of Endocan Expression and Survival in Epithelial Ovarian Cancer. Arch Gynecol Obstet (2013) 288(6):1371–6. doi: 10.1007/s00404-013-2863-3

61. Laloglu E, Kuntepe Y, Aksoy H, Topdagi YE. Serum Endocan Levels in Endometrial and Ovarian Cancers. J Clin Lab Anal (2017) 31(5):e22079. doi: 10.1002/jcla.22079

62. Zhao W, Sun M, Li S, Wang Y, Liu J. Biological and Clinical Implications of Endocan in Gastric Cancer. J Gastrointest Oncol (2014) 5(3):380–7. doi: 10.4048/jgao.20140310

63. Lu GJ, Shao CJ, Zhang Y, Wei YY, Xie WP, Kong H. Diagnostic and Prognostic Values of Endothelial-Cell-Specific Molecule-1 in Patients With Meningiomas and Gliomas. Dis Markers (2016) 2016:1750739. doi: 10.1155/2016/1750739

64. Steiner N, Hajek R, Untergasser G, Gobel G, et al. The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients With Malignant Pleural Effusions. Anticancer Res (2010) 30(7):2945–50. doi: 10.21873/anticancer.12838

65. Lu GJ, Shao CJ, Zhang Y, Wei YY, Xie WP, Kong H. Diagnostic and Prognostic Values of Endothelial-Cell-Specific Molecule-1 With Malignant Pleural Effusions in Patients With Non-Small Cell Lung Cancer. Oncotarget (2017) 8(30):49217–23. doi: 10.18632/oncotarget.17455

66. Lin L, Yeh Y, Chu C, Won JGS, Shyr Y, Chao Y, et al. Exosomal microRNA-9-3p Secreted From BMSCs Downregulates ESM1 to Suppress the Development of Bladder Cancer. Mol Ther Nucleic Acids (2019) 18:787–800. doi: 10.1016/j.omtn.2019.09.023

67. Ahmadzada T, Reid G, McKenzie DR. Fundamentals of siRNA and miRNA Therapeutics and a Review of Targeted Nanoparticle Delivery Systems in Breast Cancer. Biophys Res Commun (2018) 506:194–9. doi: 10.1016/j.biophysrev.2018.04.022

68. Adams GP, Weiner LM. Monoclonal Antibody Therapy of Cancer. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

69. Adams GP, Weiner LM. Monoclonal Antibody Therapy of Cancer. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

70. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

71. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

72. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

73. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

74. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

75. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

76. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

77. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

78. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

79. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

80. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

81. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

82. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

83. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

84. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

85. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

86. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

87. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

88. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

89. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

90. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

91. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

92. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

93. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

94. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

95. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

96. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

97. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

98. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

99. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137

100. Nat Biotechnol (2005) 23(9):1147–57. doi: 10.1038/nbt1137